Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction

References

• American Heart Association. Heart Disease and Stroke Statistics-2004 Update.
   Google Scholar
• Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005; 111:1106–13.
   PubMed Web of Science ®Google Scholar
• Katada J, Meguro T, Saito H, Ohashi A, Anzai T, Ogawa S, Yoshikawa T. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation. 2005; 111:2157–64.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. Circulation. 2004; 110:3281–8.
   PubMed Web of Science ®Google Scholar
• Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthélémy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006; 114:2604–10.
   PubMed Web of Science ®Google Scholar
• Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004; 109:2213–20.
   PubMed Web of Science ®Google Scholar
• Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998; 19:1371–6.
   PubMed Web of Science ®Google Scholar
• Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003; 5:59–65.
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999; 99:2694–701.
   PubMed Web of Science ®Google Scholar
• Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab. 2001; 86:5121–6.
   PubMed Web of Science ®Google Scholar
• Oestreicher EM, Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation. 2003; 108:2517–23.
   PubMed Web of Science ®Google Scholar
• Wehling M, Spes CH, Win N, Janson CP, Schmidt BM, Theisen K, Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab. 1998; 83:3517–22.
   PubMed Web of Science ®Google Scholar
• Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000; 141:3871–8.
   PubMed Web of Science ®Google Scholar
• Zannad F, Radauceanu A. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev. 2005; 10:71–8.
   PubMed Web of Science ®Google Scholar
• Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003; 93:69–76.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348:1309–21. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003;348:2271
   PubMed Web of Science ®Google Scholar
• Rodríguez JA, Godoy I, Castro P, Quintana JC, Chávez E, Yovanovich J, Corbalán R, Chávez A. Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study. Rev Med Chil. 1997; 125:643–52. Spanish
   PubMed Web of Science ®Google Scholar
• Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995; 76:1259–65.
   PubMed Web of Science ®Google Scholar
• Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, Christ M. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002; 39:351–8.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003; 107:2559–65.
   PubMed Web of Science ®Google Scholar
• Greenberg B, Zannad F, Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol. 2006; 97:34F–40F.
   PubMed Web of Science ®Google Scholar
• Solomon HA. Aldosterone blockade in patients with acute myocardial infarction. Circulation. 2003; 108:E173–.
   PubMed Web of Science ®Google Scholar
• Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol. 2005; 93:121–5.
   PubMed Web of Science ®Google Scholar
• Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006; 114:2572–4.
   PubMed Web of Science ®Google Scholar
• Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. Am J Cardiol. 2006; 97:26F–33F.
   PubMed Web of Science ®Google Scholar
• Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005; 111:3025–33.
   PubMed Web of Science ®Google Scholar
• G Guideri G. Death in ventricular fibrillation induced by isoproterenol in DOCA-salt pretreated rats preceded by changes in myocardial electrolytes. Life Sci. 1983; 33:1353–62.
   PubMed Web of Science ®Google Scholar
• Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001; 37:1800–7.
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995; 332:80–5.
   PubMed Web of Science ®Google Scholar
• Borghi C, Ambrosioni E. On behalf of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Group, Effects of Zofenopril on Myocardial Ischemia in Post- Myocardial Infarction Patients with Preserved Left Ventricular Function: The Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA Study. Am Heart J. 2007; 153:445e7–445e14.
   Web of Science ®Google Scholar